ORPHAZYME ANNOUNCES ESTABLISHMENT OF US SUBSIDIARY IN MASSACHUSETTS

Copenhagen, April 17, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced the creation of a US subsidiary, based in Newton, Massachusetts. The subsidiary is named Orphazyme US, Inc., and will directly support the US market to establish closer relationships with the medical, patient, and financial communities as the company expands its development program and global reach. The company also announced that Paul Merrigan will head Orphazyme US, Inc. as the US President in addition to his responsibilities as Chief Commercial Officer. 

ORPHAZYME ANNOUNCES ANNUAL REPORT 2017

Copenhagen, Denmark, March 15, 2018Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced its Annual Report for 2017. Below is a summary from the report of Orphazyme’s business progress, financial performance for the year, and guidance for 2018. The full report is attached as a PDF file and can furthermore be found on the Company's website, www.orphazyme.com.

ORPHAZYME ANNUAL REPORT 2017 PRESENTATION

Copenhagen, March 12, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Company will be hosting an investor call at which Chief Executive Officer, Anders Hinsby, and Chief Financial Officer, Anders Vadsholt, will be presenting the Orphazyme Annual Report 2017. The presentation will be followed by a Q&A session.

ORPHAZYME TO PRESENT AT COWEN & CO. 38TH ANNUAL HEALTH CARE CONFERENCE

Copenhagen, March 9, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Anders Hinsby, Chief Executive Officer at Orphazyme, will be presenting at the Cowen & Co. 38th Annual Health Care Conference in Boston, Massachusetts, USA on March 12, 2018 at 2:10-2:40 PM EST.

ORPHAZYME RECOGNIZES RARE DISEASE DAY 2018

ORPHAZYME RECOGNIZES RARE DISEASE DAY 2018

Copenhagen, February 28, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases today announced its support for Rare Disease Day. Observed annually on the last day of February, Rare Disease Day is dedicated to raise awareness about the public health issues associated with rare diseases. This is the 10th anniversary of Rare Disease Day, which was established by the European Organisation for Rare Diseases (EURORDIS), an organization representing rare disease patients in Europe, and the day is coordinated in partnership with the National Organization of Rare Disorders (NORD) in the US, with now more than 70 nations actively participating.

POSTER PRESENTATION AT WORLDSYMPOSIUM™ 2018 – ARIMOCLOMOL AS CLINICAL CANDIDATE FOR TREATMENT OF GAUCHER DISEASE

Copenhagen, February 6, 2018 – Orphazyme A/S, a Danish biotech company listed on Nasdaq Copenhagen (TICKER: ORPHA.CO), with a late-stage, orphan-drug pipeline, today announced that a poster on arimoclomol as a clinical candidate for the treatment of neuronopathic Gaucher disease will be presented at WORLDSymposium™ 2018 in San Diego, CA, USA.